Use of small molecules to increase hypoxia inducible factor (hif) activity
AssigneeBrown University
InventorsWafik EL-DEIRY, Shuai ZHAO
Life of this patent
Estimating the term…
Abstract
A method of treating heart failure and/or a stroke in a subject in need thereof is provided. The method includes administering a therapeutically effective amount of a compound that upregulates HIF-1α transcriptional activity.
Claims22
A method of treating a disease selected from heart failure and/or stroke, wounds, or chronic anemia, in a subject in need thereof, the method comprising administering a therapeutically effective amount of a compound that upregulates HIF-1α transcriptional activity, or a pharmaceutically acceptable salt thereof, to the subject.
A method of upregulating transcriptional activity of erythropoietin (EPO) in a subject in need thereof comprising administering a therapeutically effective amount of a compound of formula
- wherein
- R1 is NO2, C1-3 alkyl, or aryl substituted with 1-4 groups selected from NO2, or C1-3 alkyl;
- R3 is H and R2 is —C(═O)—NH-aryl, wherein aryl is optionally substituted with —COOH, —C(═O)C1-3 alkyl, or —C(═O)O—C1-3 alkyl,
- or R2 and R3 together with the atom to which they are attached from a 5-membered heterocycle comprising 1-2 nitrogen atoms and optionally substituted with 1-3 substituents selected from oxo, C1-3 alkyl, or aryl optionally substituted with —COOH, —C(═O)C1-3 alkyl, or —C(═O)O—C1-3 alkyl,
- or a pharmaceutically acceptable salt thereof, to the subject.
A pharmaceutical composition comprising a compound that upregulates HIF-1α transcriptional activity, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
Dependencies are inferred from the claim text.